Kubeczko M, d'Amico A, Chrabanski O, Handkiewicz-Junak D, et al. Prognostic value of baseline FDG PET/CT in HER2-positive metastatic breast cancer treated with first-line trastuzumab, pertuzumab, and docetaxel. Breast Cancer Res 2025 Dec 10. doi: 10.1186/s13058-025-02191.
PMID: 41372775